The right to treatment
We recently launched a webcast about drug therapies here on our website, it features several clips of Professor David Bates, Consultant Neurologist at University of Newcastle-upon-Tyne NHS Hospitals...
View ArticleMark up on private prescriptions
With access to NHS prescriptions of Sativex difficult in many parts of the country, a number of people have been asking for private prescriptions. This has highlighted the issue of different pharmacies...
View ArticleWalking back to happiness?
Walking. It’s such a significant ability, isn’t it? Being able to walk is one of the markers of development from babyhood to childhood. And to many of the general population in our culture, it’s...
View ArticleIn development, licensed and approved; the confusing world of MS Drugs
In my day to day work I spend a lot of time of Facebook and Twitter, I post news articles and pick up on questions people might have for the MS Trust. I notice a lot of people (including myself) get...
View ArticleNICE or a nasty tangle? Four potential new drugs, NICE, licensing, and ‘best...
Four new disease modifying drugs for relapsing/remitting MS are currently going through appraisal at NICE. These are: Teriflunomide (Aubagio) – factsheet BG-12 also known as dimethyl fumarate...
View ArticleAnti-LINGO-1, biotin and phenytoin results reported at AAN 2015
The 67th annual meeting of the American Academy of Neurology took place in Washington, April 18-25. Pre-meeting media announcements created high expectations for several presentations at the meeting,...
View Article
More Pages to Explore .....